全文获取类型
收费全文 | 1664篇 |
免费 | 122篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 75篇 |
妇产科学 | 30篇 |
基础医学 | 163篇 |
口腔科学 | 32篇 |
临床医学 | 212篇 |
内科学 | 385篇 |
皮肤病学 | 13篇 |
神经病学 | 37篇 |
特种医学 | 307篇 |
外科学 | 252篇 |
综合类 | 22篇 |
一般理论 | 1篇 |
预防医学 | 60篇 |
眼科学 | 11篇 |
药学 | 82篇 |
中国医学 | 5篇 |
肿瘤学 | 103篇 |
出版年
2023年 | 11篇 |
2022年 | 9篇 |
2021年 | 26篇 |
2020年 | 12篇 |
2019年 | 16篇 |
2018年 | 42篇 |
2017年 | 25篇 |
2016年 | 31篇 |
2015年 | 42篇 |
2014年 | 47篇 |
2013年 | 50篇 |
2012年 | 50篇 |
2011年 | 75篇 |
2010年 | 63篇 |
2009年 | 87篇 |
2008年 | 71篇 |
2007年 | 39篇 |
2006年 | 46篇 |
2005年 | 33篇 |
2004年 | 38篇 |
2003年 | 43篇 |
2002年 | 34篇 |
2001年 | 37篇 |
2000年 | 28篇 |
1999年 | 27篇 |
1998年 | 55篇 |
1997年 | 58篇 |
1996年 | 68篇 |
1995年 | 51篇 |
1994年 | 46篇 |
1993年 | 49篇 |
1992年 | 27篇 |
1991年 | 16篇 |
1990年 | 25篇 |
1989年 | 44篇 |
1988年 | 47篇 |
1987年 | 41篇 |
1986年 | 43篇 |
1985年 | 36篇 |
1984年 | 32篇 |
1983年 | 17篇 |
1982年 | 22篇 |
1981年 | 17篇 |
1980年 | 9篇 |
1979年 | 13篇 |
1977年 | 17篇 |
1976年 | 11篇 |
1975年 | 16篇 |
1973年 | 9篇 |
1969年 | 6篇 |
排序方式: 共有1794条查询结果,搜索用时 15 毫秒
1.
Auda A. Eltahla Fabio Luciani Peter A. White Andrew R. Lloyd Rowena A. Bull 《Viruses》2015,7(10):5206-5224
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens. 相似文献
2.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.